Table 1 Cohort demographics
From: A nested case–control study of predictors for tuberculosis recurrence in a large UK Centre
Case (n = 82) N (%) | Control (n = 164) N (%) | P value | |
|---|---|---|---|
Age (year, +/−SD) | 40.2 +/−17.6 | 37.4 +/−17.6 | 0.23 |
Weight (kg)a | 56 (45.5–68)** | 59 (48–68)** | 0.26 |
Gender | |||
Male | 42 (51.2) | 84 (51.2) | – |
Female | 40 (48.8) | 80 (48.8) | 1.00 |
Ethnicity | |||
White | 10 (12.2) | 20 (12.2) | – |
Afro-Caribbean | 7 (8.5) | 17 (10.4) | 0.78 |
Indian subcontinent | 61 (74.4) | 125 (76.2) | 1.0 |
Other | 4 (4.9) | 2 (1.2) | 0.18 |
Permanent residence | 81 (98.8) | 163 (99.4) | 1.00 |
UK Bornb | 25 (30.5) | 37 (22.5) | 0.16 |
Habitual alcohol consumptionc | 17 (23.6) | 20 (12.4) | 0.03 |
Habitual tobacco smokingd | 20 (26.3) | 19 (11.7) | 0.01 |
BCG vaccinatede | 31 (79.5) | 73 (81.1) | 0.81 |
Comorbidities | |||
Diabetes mellitus | 9 (11.0) | 15 (9.2) | 0.65 |
Solid organ transplant± | 0 | 1 (0.6) | 1.00 |
Cancer | 0 | 3 (1.8) | 0.55 |
End stage renal failure | 1 (1.2) | 3 (1.8) | 1.00 |
Rheumatological conditions¶ | 3 (3.7) | 1 (0.6) | 0.11 |
HIV-1 seropositivity | 5 (6.1) | 6 (3.7) | 0.51 |
Vitamin D deficiencyf | 24 (64.8) | 52 (69.3) | 0.67 |
Laboratory | |||
Haemoglobing (g/dl +/−SD) | 11.7+/−1.8 | 12.2+/−1.9 | 0.11 |
White cell counth (×109 cells/L) | 7.5 (6.0–9.6)** | 7.7 (5.9–9.5)** | 0.91 |
Creatininei (μmol/l) | 70.0 (61.5–79.0)** | 71.0 (61.0–83.0)** | 0.46 |
Primary disease site | |||
PTB | 45 (54.8) | 68 (41.4) | – |
PTB + EPTB | 10 (12.2) | 31 (19.0) | 0.09 |
EPTB | 27 (33.0) | 65 (39.6) | 0.14 |
Pulmonary cavitation | 19 (23.2) | 23 (14.0) | 0.11 |
Microbiology | |||
AFB smear positivej | 30 (41.7) | 42 (27.7) | 0.01 |
Mtb culture positivek | 56 (76.7) | 93 (66.9) | 0.16 |
Drug resistancel | 7 (12.5) | 6 (6.5) | 0.24 |
Treatment | |||
Standard regimen | 68 (82.9) | 145 (88.4) | 0.24 |
ADR | |||
No ADR | 64 (78.0) | 143 (87.2) | – |
Grade 1/2 | 4 (4.9) | 7 (4.3) | 0.74 |
Grade 3/4 | 14 (17.1) | 14 (8.5) | 0.06 |
Treatment interruption (days) | 0 (0–0)** | 0 (0–0)** | 0.96 |
Immunosuppressing drugs | 17 (20.7) | 16 (9.8) | 0.03 |
Duration (days) | 168 (168–273)** | 168 (168–274)** | 0.50 |